Relafen 750, pharmacologically known as naproxen, represents a significant case study from a pharmacological pharmacy standpoint. The drug exhibits its turinabol pain-relieving effect primarily by reducing the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby suppressing prostaglandin production . The specific inhibition of COX-